PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29534723
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180412
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 18
IP  - 1
DP  - 2018 Mar 13
TI  - Plumbagin induces RPE cell cycle arrest and apoptosis via p38 MARK and
      PI3K/AKT/mTOR signaling pathways in PVR.
PG  - 89
LID - 10.1186/s12906-018-2155-3 [doi]
AB  - BACKGROUND: This study aimed to explore the effects of plumbagin (PLB) on ARPE-19
      cells and underlying mechanism. METHODS: Cultured ARPE-19 cells were treated with
      various concentrations (0, 5, 15, and 25 muM) of PLB for 24 h or with 15 muM PLB 
      for 12, 24 and 48 h. Then cell viability was evaluated by MTT assay and DAPI
      staining, while apoptosis and cell cycle progression of ARPE cells were assessed 
      by flow cytometric analysis. Furthermore, the level of main regulatory proteins
      was examinated by Western boltting and the expression of relative mRNA was tested
      by Real-Time PCR. RESULTS: PLB exhibited potent inducing effects on cell cycle
      arrest at G2/M phase and apoptosis of ARPE cells via the modulation of Bcl-2
      family regulators in a concentration- and time-dependent manner. PLB induced
      inhibition of phosphatidylinositol 3-kinase (PI3K) and p38 mitogen-activated
      protein kinase (p38 MAPK) signaling pathways contributing to the
      anti-proliferative activities in ARPE cells. CONCLUSIONS: This is the first
      report to show that PLB could inhibit the proliferation of RPE cells through
      down-regulation of modulatory signaling pathways. The results open new avenues
      for the use of PLB in prevention and treatment of proliferative
      vitreoretinopathy.
FAU - Chen, Haiting
AU  - Chen H
AD  - Department of Ophthalmology, Second Hospital of Hebei Medical University, No. 215
      Peace West Road, Qiaoxi District, Shijiazhuang, Hebei, 050000, China.
AD  - Department of Ophthalmology, Cangzhou Central Hospital, No. 16 Xinhua West Road, 
      Cangzhou, Hebei, 061000, China.
FAU - Wang, Huifang
AU  - Wang H
AD  - Department of Ophthalmology, Second Hospital of Hebei Medical University, No. 215
      Peace West Road, Qiaoxi District, Shijiazhuang, Hebei, 050000, China.
FAU - An, Jianbin
AU  - An J
AD  - Department of Ophthalmology, Second Hospital of Hebei Medical University, No. 215
      Peace West Road, Qiaoxi District, Shijiazhuang, Hebei, 050000, China.
FAU - Shang, Qingli
AU  - Shang Q
AD  - Department of Ophthalmology, Second Hospital of Hebei Medical University, No. 215
      Peace West Road, Qiaoxi District, Shijiazhuang, Hebei, 050000, China.
FAU - Ma, Jingxue
AU  - Ma J
AD  - Department of Ophthalmology, Second Hospital of Hebei Medical University, No. 215
      Peace West Road, Qiaoxi District, Shijiazhuang, Hebei, 050000, China.
      [email protected]
LA  - eng
PT  - Journal Article
DEP - 20180313
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Naphthoquinones)
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - YAS4TBQ4OQ (plumbagin)
SB  - IM
MH  - Apoptosis/*drug effects
MH  - Cell Cycle Checkpoints/*drug effects
MH  - Cell Line
MH  - Cell Survival/drug effects
MH  - Drugs, Chinese Herbal/*pharmacology
MH  - Epithelial Cells/cytology/drug effects/metabolism
MH  - Humans
MH  - Naphthoquinones/*pharmacology
MH  - Phosphatidylinositol 3-Kinases/genetics/metabolism
MH  - Plumbaginaceae/*chemistry
MH  - Proto-Oncogene Proteins c-akt/genetics/metabolism
MH  - Retinal Pigment Epithelium/cytology/*drug effects/metabolism
MH  - Signal Transduction/*drug effects
MH  - TOR Serine-Threonine Kinases/genetics/metabolism
MH  - Vitreoretinopathy, Proliferative/drug
      therapy/genetics/metabolism/*physiopathology
MH  - p38 Mitogen-Activated Protein Kinases/genetics/metabolism
PMC - PMC5851073
OTO - NOTNLM
OT  - Plumbagin
OT  - Proliferation
OT  - RPE
EDAT- 2018/03/15 06:00
MHDA- 2018/04/13 06:00
CRDT- 2018/03/15 06:00
PHST- 2017/06/19 00:00 [received]
PHST- 2018/03/02 00:00 [accepted]
PHST- 2018/03/15 06:00 [entrez]
PHST- 2018/03/15 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
AID - 10.1186/s12906-018-2155-3 [doi]
AID - 10.1186/s12906-018-2155-3 [pii]
PST - epublish
SO  - BMC Complement Altern Med. 2018 Mar 13;18(1):89. doi: 10.1186/s12906-018-2155-3.